{"id":"priorixtm","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"2-5","effect":"Rash"},{"rate":"<1","effect":"Parotitis (mumps-like symptoms)"},{"rate":"1-3","effect":"Arthralgia/arthritis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Priorix contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals without causing disease, thereby triggering both humoral and cellular immune responses. This leads to the production of protective antibodies and memory immune cells against all three viral pathogens. The vaccine provides long-term immunity against measles, mumps, and rubella infections.","oneSentence":"Priorix is a live attenuated combination vaccine that stimulates immune responses against measles, mumps, and rubella viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:07.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, and rubella in children and adults"}]},"trialDetails":[{"nctId":"NCT01245049","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Tetanus","enrollment":387},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00751348","phase":"PHASE3","title":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Measles, Varicella, Mumps","enrollment":475}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PriorixTM","genericName":"PriorixTM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Priorix is a live attenuated combination vaccine that stimulates immune responses against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}